Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

In this page

Clinical Trial

NCT03525600 Completed
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Phase 3
Interventional

Disease

Disease type

Geographic Atrophy

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

31/08/2018

Closing date

21/06/2021

Inclusion criteria :

More

Exclusion criteria :

More

Funding

private

Members involved

Others investigators

Pr Frank Holz

Representative

Germany

See more

Dr Philipp Herrmann

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Claudia Priglinger

Representative

Germany

See more

ERN EYE member investigating site

HCP : Principal investigators